15 results on '"Eichenauer, Dennis Alexander"'
Search Results
2. Handoffs in the intensive care unit
- Author
-
Reifarth, Eyleen, primary, Naendrup, Jan-Hendrik, additional, Garcia Borrega, Jorge, additional, Altenrath, Lisa, additional, Shimabukuro-Vornhagen, Alexander, additional, Eichenauer, Dennis Alexander, additional, Kochanek, Matthias, additional, and Böll, Boris, additional
- Published
- 2024
- Full Text
- View/download PDF
3. Airway Pressure Release Ventilation in COVID-19-Associated Acute Respiratory Distress Syndrome—A Multicenter Propensity Score–Matched Analysis.
- Author
-
Naendrup, Jan-Hendrik, Steinke, Jonathan, Garcia Borrega, Jorge, Stoll, Sandra Emily, Michelsen, Per Ole, Assion, Yannick, Shimabukuro-Vornhagen, Alexander, Eichenauer, Dennis Alexander, Kochanek, Matthias, and Böll, Boris
- Subjects
ADULT respiratory distress syndrome ,COVID-19 ,VENTILATION ,INTENSIVE care units ,CRITICAL care medicine - Abstract
Background: There are limited and partially contradictory data on the effects of airway pressure release ventilation (APRV) in COVID-19-associated acute respiratory distress syndrome (CARDS). Therefore, we analyzed the clinical outcome, complications, and longitudinal course of ventilation parameters and laboratory values in patients with CARDS, who were mechanically ventilated using APRV. Methods: Respective data from 4 intensive care units (ICUs) were collected and compared to a matched cohort of patients receiving conventional low tidal volume ventilation (LTV). Propensity score matching was performed based on age, sex, blood gas analysis, and APACHE II score at admission, as well as the implementation of prone positioning. Findings: Forty patients with CARDS, who were mechanically ventilated using APRV, and 40 patients receiving LTV were matched. No significant differences were detected for tidal volumes per predicted body weight, peak pressure values, and blood gas analyses on admission, 6 h post admission as well as on day 3 and day 7. Regarding ICU survival, no significant difference was identified between APRV patients (40%) and LTV patients (42%). Median duration of mechanical ventilation and duration of ICU treatment were comparable in both groups. Similar complication rates with respect to ventilator-associated pneumonia, septic shock, thromboembolic events, barotrauma, as well as the necessity for hemodialysis were detected for both groups. Clinical characteristics that were associated with increased mortality in a Cox proportional hazards regression analysis included age (hazard ratio [HR] 1.08, 95% confidence interval [CI] 1.04-1.1; P <.001), severe acute respiratory distress syndrome (HR 2.62, 95% CI 1.02-6.7; P =.046) and the occurrence of septic shock (HR 17.18, 95% CI 2.06-143.2; P =.009), but not the ventilation mode. Interpretation: Intensive care unit survival, duration of mechanical ventilation, and ICU treatment as well as ventilation-associated complication rates were equivalent using APRV compared to conventional LTV in patients with CARDS. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
4. Reactivation of EBV and CMV in Severe COVID-19—Epiphenomena or Trigger of Hyperinflammation in Need of Treatment? A Large Case Series of Critically ill Patients
- Author
-
Eichenauer Dennis Alexander, Shimabukuro-Vornhagen Alexander, Garcia Borrega Jorge, Jan-Hendrik Naendrup, Böll Boris, and Kochanek Matthias
- Subjects
Ganciclovir ,Epstein-Barr Virus Infections ,Herpesvirus 4, Human ,medicine.medical_specialty ,ARDS ,Critical Illness ,Congenital cytomegalovirus infection ,Cytomegalovirus ,Critical Care and Intensive Care Medicine ,law.invention ,Cohort Studies ,Sepsis ,law ,Internal medicine ,medicine ,Humans ,Retrospective Studies ,business.industry ,COVID-19 ,medicine.disease ,Intensive care unit ,Cytomegalovirus Infections ,Virus Activation ,Rituximab ,business ,Viral load ,Cohort study ,medicine.drug - Abstract
Background Reactivation of viruses such as Epstein-Barr virus (EBV) and cytomegalovirus (CMV) are common in critically ill patients and have been described in patients with severe COVID-19. However, it is unclear whether these reactivations are associated with increased mortality and whether targeted treatments are beneficial. Methods In a retrospective single-center cohort study, patients with severe COVID-19 treated on our intensive care unit (ICU) were screened for EBV and CMV reactivation as detected by polymerase chain reaction. If present, patient characteristics, temporal connections to severe acute respiratory syndrome coronavirus 2 diagnosis and corticosteroid use, the use of targeted treatments as well as the course of disease and outcome were analyzed. As control group, non-COVID-19 patients with sepsis, treated within the same time period on our ICU, served as control group to compare incidences of viral reactivation. Results In 19 (16%) of 117 patients with severe COVID-19 treated on our ICU EBV reactivations were identified, comparable 18 (14%) of 126 in the non-COVID-19 control group ( P = .672). Similarly, in 11 (9%) of 117 patients CMV reactivations were identified, comparable to the 16 (13%) of 126 in the non-COVID-19 sepsis patients ( P = .296). The majority of EBV (58%) and CMV reactivations (55%) were detected in patients under systemic corticosteroid treatment. 7 (37%) of 19 patients with EBV reactivation survived the ICU stay, 2 (29%) of 7 patients with rituximab treatment and 5 (42%) of 12 patients without treatment ( P = .568). Five (50%) of 10 patients with CMV reactivation survived the ICU stay, 5 (83%) of 6 patients with ganciclovir treatment and 0 of 4 patients without treatment ( P = .048). Follow-up analysis in these patients showed that the initiation of treatment lead to decrease in viral load. Conclusion Critically ill patients with COVID-19 are at a high risk for EBV and CMV reactivations. Whether these reactivations are a cause of hyperinflammation and require targeted treatment remains uncertain. However, in patients with clinical deterioration or signs of hyperinflammation targeted treatment might be beneficial and warrants further studying.
- Published
- 2021
5. Reactivation of EBV and CMV in Severe COVID-19—Epiphenomena or Trigger of Hyperinflammation in Need of Treatment? A Large Case Series of Critically ill Patients
- Author
-
Naendrup, Jan-Hendrik, primary, Garcia Borrega, Jorge, additional, Eichenauer, Dennis Alexander, additional, Shimabukuro-Vornhagen, Alexander, additional, Kochanek, Matthias, additional, and Böll, Boris, additional
- Published
- 2021
- Full Text
- View/download PDF
6. Clinical Course and Outcome of Patients with SARS-CoV-2 Alpha Variant Infection Compared to Patients with SARS-CoV-2 Wild-Type Infection Admitted to the ICU
- Author
-
Garcia Borrega, Jorge, primary, Naendrup, Jan-Hendrik, additional, Heindel, Katrin, additional, Hamacher, Laura, additional, Heger, Eva, additional, Di Cristanziano, Veronica, additional, Deppe, Antje-Christin, additional, Dusse, Fabian, additional, Wetsch, Wolfgang Alois, additional, Eichenauer, Dennis Alexander, additional, Shimabukuro-Vornhagen, Alexander, additional, Böll, Boris, additional, and Kochanek, Matthias, additional
- Published
- 2021
- Full Text
- View/download PDF
7. Reactivation of EBV and CMV in Severe COVID-19--Epiphenomena or Trigger of Hyperinflammation in Need of Treatment? A Large Case Series of Critically ill Patients.
- Author
-
Naendrup, Jan-Hendrik, Garcia Borrega, Jorge, Eichenauer, Dennis Alexander, Shimabukuro-Vornhagen, Alexander, Kochanek, Matthias, and Böll, Boris
- Subjects
EPSTEIN-Barr virus ,CYTOMEGALOVIRUSES ,CORONAVIRUS diseases ,INTENSIVE care units ,SARS disease ,CRITICALLY ill - Abstract
Background: Reactivation of viruses such as Epstein-Barr virus (EBV) and cytomegalovirus (CMV) are common in critically ill patients and have been described in patients with severe COVID-19. However, it is unclear whether these reactivations are associated with increased mortality and whether targeted treatments are beneficial. Methods: In a retrospective single-center cohort study, patients with severe COVID-19 treated on our intensive care unit (ICU) were screened for EBV and CMV reactivation as detected by polymerase chain reaction. If present, patient characteristics, temporal connections to severe acute respiratory syndrome coronavirus 2 diagnosis and corticosteroid use, the use of targeted treatments as well as the course of disease and outcome were analyzed. As control group, non-COVID-19 patients with sepsis, treated within the same time period on our ICU, served as control group to compare incidences of viral reactivation. Results: In 19 (16%) of 117 patients with severe COVID-19 treated on our ICU EBV reactivations were identified, comparable 18 (14%) of 126 in the non-COVID-19 control group (P=.672). Similarly, in 11 (9%) of 117 patients CMV reactivations were identified, comparable to the 16 (13%) of 126 in the non-COVID-19 sepsis patients (P=.296). The majority of EBV (58%) and CMV reactivations (55%) were detected in patients under systemic corticosteroid treatment. 7 (37%) of 19 patients with EBV reactivation survived the ICU stay, 2 (29%) of 7 patients with rituximab treatment and 5 (42%) of 12 patients without treatment (P=.568). Five (50%) of 10 patients with CMV reactivation survived the ICU stay, 5 (83%) of 6 patients with ganciclovir treatment and 0 of 4 patients without treatment (P=.048). Follow-up analysis in these patients showed that the initiation of treatment lead to decrease in viral load. Conclusion: Critically ill patients with COVID-19 are at a high risk for EBV and CMV reactivations. Whether these reactivations are a cause of hyperinflammation and require targeted treatment remains uncertain. However, in patients with clinical deterioration or signs of hyperinflammation targeted treatment might be beneficial and warrants further studying. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
8. Clinical Course and Outcome of Patients with SARS-CoV-2 Alpha Variant Infection Compared to Patients with SARS-CoV-2 Wild-Type Infection Admitted to the ICU
- Author
-
Garcia Borrega, Jorge, Naendrup, Jan-Hendrik, Heindel, Katrin, Hamacher, Laura, Heger, Eva, Di Cristanziano, Veronica, Deppe, Antje-Christin, Dusse, Fabian, Wetsch, Wolfgang Alois, Eichenauer, Dennis Alexander, Shimabukuro-Vornhagen, Alexander, Boell, Boris, Kochanek, Matthias, Garcia Borrega, Jorge, Naendrup, Jan-Hendrik, Heindel, Katrin, Hamacher, Laura, Heger, Eva, Di Cristanziano, Veronica, Deppe, Antje-Christin, Dusse, Fabian, Wetsch, Wolfgang Alois, Eichenauer, Dennis Alexander, Shimabukuro-Vornhagen, Alexander, Boell, Boris, and Kochanek, Matthias
- Abstract
The alpha variant of the severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) is associated with higher transmissibility and possibly higher mortality compared with wild-type SARS-CoV-2. However, few data are available on the clinical course of infections with the alpha variant compared with wild-type SARS-CoV-2 in critically ill patients in intensive care units (ICUs). Therefore, we retrospectively analyzed patients admitted to our ICU due to SARS-CoV-2 Alpha variant infection and compared characteristics and course to patients with SARS-CoV-2 wild-type infection. The median age of patients with Alpha variant infections was 57 years compared to 62 years in the wild-type group. ICU survival was 41/80 (51%) in the Alpha variant group and 35/80 (44%) in the wild-type group (p = 0.429). Results of a matched-pair analysis based on age and sex illustrated that 45/58 patients (77.6%) in the Alpha variant group and 38/58 (65.5%) patients in the wild-type group required mechanical ventilation (p = 0.217). ICU survival was documented for 28/58 patients (48.3%) in the Alpha variant group and 27/58 patients (46.6%) in the wild-type group (p = 1). Thus, ICU mortality among patients with SARS-CoV-2 infections remains high. Although the Alpha variant group included younger patients requiring mechanical ventilation, no significant differences between patients with the SARS-CoV-2 Alpha variant and the SARS-CoV-2 wild-type, respectively, were detected with respect to clinical course and ICU mortality. For future VOCs, we believe it would be important to obtain valid and rapid data on the clinical course of critically ill patients who test positive for COVID-19 in order to perform appropriate epidemiological planning of intensive care capacity.
- Published
- 2021
9. Histopathological growth patterns in patients with advanced nodular lymphocyte-predominant Hodgkin lymphoma treated within the randomized HD18 study: a report from the German Hodgkin Study Group
- Author
-
Eichenauer, Dennis Alexander, Bühnen, Ina, Kreissl, Stefanie, Goergen, Helen, Fuchs, Michael, Tresckow, Bastian von, Rosenwald, Andreas, Klapper, Wolfram, Hansmann, Martin-Leo, Möller, Peter, Bernd, Heinz-Wolfram, Feller, Alfred C., Engert, Andreas, Borchmann, Peter, Hartmann, Sylvia, Eichenauer, Dennis Alexander, Bühnen, Ina, Kreissl, Stefanie, Goergen, Helen, Fuchs, Michael, Tresckow, Bastian von, Rosenwald, Andreas, Klapper, Wolfram, Hansmann, Martin-Leo, Möller, Peter, Bernd, Heinz-Wolfram, Feller, Alfred C., Engert, Andreas, Borchmann, Peter, and Hartmann, Sylvia
- Abstract
We retrospectively investigated histopathological growth patterns in individuals with advanced nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) treated within the randomized HD18 study. In all, 35/60 patients (58%) presented with atypical growth patterns. Patients with atypical growth patterns more often had stage IV disease (P = 0·0354) and splenic involvement (P = 0·0048) than patients with typical growth patterns; a positive positron emission tomography after two cycles of chemotherapy (PET-2) tended to be more common (P = 0·1078). Five-year progression-free survival [hazard ratio (HR) = 0·86; 95% confidence interval (CI) = 0·49–1·47] and overall survival (HR = 0·85; 95% CI = 0·49–1·51) did not differ between the groups after study treatment with PET-2-guided escalated BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone). Thus, advanced NLPHL is often associated with atypical growth patterns but their prognostic impact is compensated by PET-2-guided escalated BEACOPP.
- Published
- 2021
10. SARS-COV-2 Infektionsmanagement
- Author
-
Eichenauer, Dennis Alexander, Shimabukuro-Vornhagen, Alexander, Fätkenheuer, Gerd, Kochanek, Matthias, Böll, Boris, Köhler, Philipp, Rybniker, Jan, Jung, Norma, Cornely, Oliver Andreas, Universitätsklinikum Köln. Klinik I Für Innere Medizin, Grüll, Henning, Kolibay, Felix, Fuhr, Uwe, and Klein, Florian
- Subjects
Medizin und Gesundheit - Published
- 2020
- Full Text
- View/download PDF
11. Covid-19/Influenza-Associated Pulmonary Aspergillosis - Management
- Author
-
Hoenigl, Martin, Ostrosky-Zeichner, Luis, Cornely, Oliver Andreas, Universitätsklinikum Köln. Klinik I Für Innere Medizin, Eichenauer, Dennis Alexander, Meis, Jacques F., Böll, Boris, and Köhler, Philipp
- Subjects
Medizin und Gesundheit ,COVID-19 - Published
- 2020
- Full Text
- View/download PDF
12. SARS-COV-2 Management
- Author
-
Eichenauer, Dennis Alexander, Shimabukuro-Vornhagen, Alexander, Fätkenheuer, Gerd, Kochanek, Matthias, Böll, Boris, Köhler, Philipp, Rybniker, Jan, Jung, Norma, Cornely, Oliver Andreas, Universitätsklinikum Köln. Klinik I Für Innere Medizin, Grüll, Henning, Kolibay, Felix, Fuhr, Uwe, and Klein, Florian
- Subjects
Medizin und Gesundheit - Published
- 2020
- Full Text
- View/download PDF
13. The time to relapse correlates with the histopathological growth pattern in nodular lymphocyte predominant Hodgkin lymphoma
- Author
-
Hartmann, Sylvia, Plütschow, Annette, Mottok, Anja, Bernd, Heinz-Wolfram, Feller, Alfred C., Ott, German, Cogliatti, Sergio, Fend, Falko, Quintanilla‐Martinez, Leticia, Stein, Harald, Klapper, Wolfram, Möller, Peter, Rosenwald, Andreas, Engert, Andreas, Hansmann, Martin-Leo, Eichenauer, Dennis Alexander, Hartmann, Sylvia, Plütschow, Annette, Mottok, Anja, Bernd, Heinz-Wolfram, Feller, Alfred C., Ott, German, Cogliatti, Sergio, Fend, Falko, Quintanilla‐Martinez, Leticia, Stein, Harald, Klapper, Wolfram, Möller, Peter, Rosenwald, Andreas, Engert, Andreas, Hansmann, Martin-Leo, and Eichenauer, Dennis Alexander
- Abstract
Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) can present with different histopathological growth patterns. The impact of these histopathological growth patterns on relapse characteristics is unknown. We therefore analyzed paired biopsies obtained at initial diagnosis and relapse from 33 NLPHL patients who had received first‐line treatment within German Hodgkin Study Group (GHSG) trial protocols, and from a second cohort of 41 relapsed NLPHL patients who had been treated outside GHSG studies. Among the 33 GHSG patients, 21 patients presented with a typical growth pattern at initial diagnosis, whereas 12 patients had a variant histology. The histopathological growth patterns at initial diagnosis and at relapse were consistent in 67% of cases. A variant histology at initial diagnosis was associated with a shorter median time to lymphoma recurrence (2.8 vs 5.2 years; P = .0219). A similar tendency towards a shorter median time to lymphoma recurrence was observed for patients presenting with a variant histology at relapse, irrespective of the growth pattern at initial diagnosis. Results obtained from the 41 NLPHL patients who had been treated outside GHSG studies were comparable (median time to lymphoma recurrence for variant histology vs typical growth pattern at initial diagnosis: 1.5 vs 7.0 years). In conclusion, the histopathological growth pattern remains consistent at relapse in the majority of NLPHL cases, and has major impact on the time of relapse.
- Published
- 2019
14. Soluble CD30 receptor from Hodgkin cells stimulates granulocytes to release angiogenic interleukin‐8
- Author
-
Hansen, Hinrich Peter, primary, Simhadri, Vijaya Lakshmi, additional, Eichenauer, Dennis Alexander, additional, Engert, Andreas, additional, and Von Strandmann, Elke Pogge, additional
- Published
- 2008
- Full Text
- View/download PDF
15. [Handoffs in the intensive care unit].
- Author
-
Reifarth E, Naendrup JH, Garcia Borrega J, Altenrath L, Shimabukuro-Vornhagen A, Eichenauer DA, Kochanek M, and Böll B
- Subjects
- Humans, Germany, Checklist, Interdisciplinary Communication, Medical Errors prevention & control, Patient Care Team organization & administration, Critical Care standards, Patient Handoff organization & administration, Patient Handoff standards, Intensive Care Units, Patient Safety
- Abstract
Background: Effective handoffs in the intensive care unit (ICU) are key to patient safety., Purpose: This article aims to raise awareness of the significance of structured and thorough handoffs and highlights possible challenges as well as means for improvement., Materials and Methods: Based on the available literature, the evidence regarding handoffs in ICUs is summarized and suggestions for practical implementation are derived., Results: The quality of handoffs has an impact on patient safety. At the same time, communication in the intensive care setting is particularly challenging due to the complexity of cases, a disruptive work environment, and a multitude of inter- and intraprofessional interactions. Hierarchical team structures, deficiencies in feedback and error-management culture, (technical) language barriers in communication, as well as substantial physical and psychological stress may negatively influence the effectiveness of handoffs. Sets of interventions such as the implementation of checklists, mnemonics, and communication workshops contribute to a more structured and thorough handoff process and have the potential to significantly improve patient safety., Conclusion: Effective handoffs are the cornerstone of high-quality and safe patient care but face particular challenges in ICUs. Interventional measures such as structuring handoff concepts and periodic communication trainings can help to improve handoffs and thus increase patient safety., (© 2024. The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature.)
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.